Glioblastoma multiforme targeted delivery of docetaxel using bevacizumab-modified nanostructured lipid carriers impair in vitro cell growth and in vivo tumor progression

•Nanostructured lipid carriers containing docetaxel were fabricated by fusion-emulsification followed by sonication.•Bevacizumab-modified docetaxel-loaded nanostructured lipid carriers (BVZ-NLC-DTX) were prepared via thiol reaction method using DSPE-PEG2000-Maleimide and thiolated BVZ.•After fabrication, docetaxel and bevacizumab activities were preserved.•BVZ-NLC-DTX was able to promote cell death by apoptosis specifically in glioblastoma cells but not in healthy immune cells.•BVZ-NLC-DTX was able to reduce up to 70% of orthotopic preclinical tumor model in rat, while free-DTX did not.